Wockhardt has received approval from the United States Food & Drug Administration (US FDA) for an ANDA for 50mg injection of Decitabine, which is used to treat certain forms of cancer. Wockhardt's Decitabine Injection is a generic version of Dacogen, marketed in USA and other countries by Otsuka.
According to IQVIA February 2019 data, the product has sales of $120 million in the US.
Wockhardt will be launching this product in the United States, in a short period of time. With its nationwide distribution network and its excellent relationship with all major trade, retail and institutional customers, Wockhardt is already a significant player in the US pharmaceutical market.
The product is being manufactured at a contract manufacturing facility, based near Hyderabad, India.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)